Pamiparib
A PARP inhibitor anti-cancer drug compound
- US: Investigational New Drug
- Rx in China
- (2R)-14-Fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
- 1446261-44-4
- 135565554
- DB14769
- 58805610
- 8375F9S90C
- D11426
- ChEMBL4112930
- Interactive image
- C[C@]12CCCN1CC3=NNC(=O)C4=C5C3=C2NC5=CC(=C4)F
InChI
- InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
- Key:DENYZIUJOTUUNY-MRXNPFEDSA-N
Pamiparib, sold under the brand name Partruvix, is a pharmaceutical drug used for the treatment of various types of cancer. Pamiparib is a member of the PARP inhibitor drug class.[1]
In China, it is approved for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube, and primary peritoneal cancers previously treated with two or more lines of chemotherapy.[2]
It is currently under investigation for the treatment of other forms of cancer.[3][1]
References
- ^ a b Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, et al. (September 2020). "Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor". Neoplasia. 22 (9): 431–440. doi:10.1016/j.neo.2020.06.009. PMC 7350150. PMID 32652442.
- ^ Markham A (July 2021). "Pamiparib: First Approval". Drugs. 81 (11): 1343–1348. doi:10.1007/s40265-021-01552-8. PMID 34287805.
- ^ Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, et al. (September 2023). "Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial". British Journal of Cancer. 129 (5): 797–810. doi:10.1038/s41416-023-02349-0. PMC 10449784. PMID 37474720.
- v
- t
- e